Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 17, 2020

Primary Completion Date

August 9, 2024

Study Completion Date

March 31, 2026

Conditions
Salivary Gland Cancer
Interventions
DRUG

Darolutamide

Darolutamide at a dose of 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally.

DRUG

Goserelin

Goserelin at a dose of 3.6 mg will be administered subcutaneously every 4 weeks.

Trial Locations (12)

466-8560

Nagoya University Hospital, Nagoya

260-8677

Chiba University Hospital, Chiba

277-8577

National Cancer Center Hospital East, Kashiwa

810-8563

National Hospital Organization Kyushu Medical Center, Fukuoka

060-8648

Hokkaido University Hospital, Sapporo

650-0017

Kobe University Hospital, Kobe

236-0004

Yokohama City University Hospital, Yokohama

980-8574

Tohoku University Hospital, Sendai

541-8567

Osaka International Cancer Institute, Osaka

105-0003

The Jikei University Hospital, Tokyo

113-8519

Tokyo Medical And Dental University Hospital, Tokyo

160-0023

Tokyo Medical University Hospital, Tokyo

All Listed Sponsors
collaborator

Bayer Yakuhin, Ltd.

INDUSTRY

lead

National Cancer Center Hospital East

OTHER